 |
 |
On Mon 03 Nov, janet paterson wrote: > i wonder if the problem here is > simply the wording in the books and pamphlets you mention > > maybe the description > 'effective therapeutic life of levodopa' > really should mean the > 'honeymoon period' > where tweaking and adjusting are not critical to > preventing the 'on and off' phenomenon > > viz this description extracted from > dr. kurth's press release on tolcapone: > > words in [] inserted by myself for clarity You make my point nicely, Janet: Yu have had to add words in [ ] to achieve clarity. As I wrote earlier Press releases for a new drug are hardly the place where you wuld go to read an objective assessment of levodopa. Basically, all I am trying to do is put levodopa in its rightful place, which, with all its admitted drawbacks, is still number 1. None of the alternatives can match the range of effectiveness of levodopa, although combinations of the old and the new seem to me to be even better. Regards, -- Brian Collins <[log in to unmask]>